Study Subjects | Positivity for IgM (%) | Negativity for IgM (%) |
---|---|---|
Neuro-CHIKV patients (n = 46) | 22 (48%) | 24 (52%) |
Confirmed (n = 9) | 8 (89%) | 1 (11%) |
   Encephalitis (n = 4) | 3 (75%) | 1 (25%) |
   Myelopathy (n = 2) | 2 (100%) | 0 |
   Myeloneuropathy (n = 1) | 1 (100%) | 0 |
   Peripheral Neuropathy (n = 1) | 1 (100%) | 0 |
   Myopathy (n = 1) | 1 (100%) | 0 |
Suspected (n = 37) | 14 (38%) | 23 (62%) |
   Encephlitis (n = 20) | 5(25%) | 15 (75%) |
   Myelopathy (n = 5) | 3 (60%) | 2 (40%) |
   Myeloneuropathy (n = 6) | 4 (67%) | 2 (33%) |
   Peripheral Neuropathy (n = 6) | 2 (33%) | 4 (67%) |
Non-CHIKV patients (n = 15) | 4 (27%) | 11 (73%) |